A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease

A 6-Year Postmarketing Safety and Clinical Outcome Study of LEQEMBI® in the Treatment of Alzheimer's Disease Using Real-World Data From South Korean Patients Enrolled Into the South Korean JOint RegistrY for ALZheimer's Treatment and Diagnostics (JOY-ALZ) Registry

The primary purpose of this study is to evaluate safety of LEQEMBI in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in patients treated with LEQEMBI.

Inclusion Criteria:

• Enrolled in JOY-ALZ before the decision to treat with LEQEMBI
• The clinical decision to treat with LEQEMBI has already been made
• Provides written informed consent for the use of medical information to be shared with Eisai Korea Inc.

Exclusion Criteria:

• Currently participating in an interventional clinical study